MTOR and neoplasm: Accordingly, because the binding of insulin to its receptors activates the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling cascade, activating mutations in the PIK3CA oncogene might be expected to determine tumor response to DR-like pharmacological strategies targeting the insulin and mTOR pathways (27, 28).